

Pierre Van Damme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6531208/publications.pdf>

Version: 2024-02-01

264
papers

12,632
citations

29994

54
h-index

31759

101
g-index

280
all docs

280
docs citations

280
times ranked

13988
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
3	The global impact of vaccination against hepatitis B: A historical overview. <i>Vaccine</i> , 2008, 26, 6266-6273.	1.7	346
4	Knowledge, Attitudes and Practices in Travel-related Infectious Diseases: The European Airport Survey. <i>Journal of Travel Medicine</i> , 2004, 11, 3-8.	1.4	308
5	Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. <i>Vaccine</i> , 2009, 27, 454-459.	1.7	285
6	Hepatitis B and the Need for a Booster Dose. <i>Clinical Infectious Diseases</i> , 2011, 53, 68-75.	2.9	246
7	Hepatitis A booster vaccination: is there a need?. <i>Lancet, The</i> , 2003, 362, 1065-1071.	6.3	235
8	Rationale for pertussis booster vaccination throughout life in Europe. <i>Lancet Infectious Diseases, The</i> , 2011, 11, 557-570.	4.6	222
9	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
10	Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. <i>Journal of Hepatology</i> , 2018, 68, 167-184.	1.8	194
11	Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004-2005: The REVEAL Study. <i>Journal of Infectious Diseases</i> , 2007, 195, S4-S16.	1.9	181
12	Vaccines and routine immunization strategies during the COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 400-407.	1.4	165
13	Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. <i>Vaccine</i> , 2016, 34, 142-150.	1.7	147
14	Integration of hepatitis B vaccination into national immunisation programmes. <i>BMJ: British Medical Journal</i> , 1997, 314, 1033-1033.	2.4	128
15	The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. <i>Lancet, The</i> , 2019, 394, 148-158.	6.3	123
16	Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. <i>Cell Host and Microbe</i> , 2020, 27, 736-751.e8.	5.1	118
17	Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. <i>Vaccine</i> , 2013, 31, 685-690.	1.7	115
18	A review of the long-term protection after hepatitis A and B vaccination. <i>Travel Medicine and Infectious Disease</i> , 2007, 5, 79-84.	1.5	111

#	ARTICLE	IF	CITATIONS
19	Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. <i>Vaccine</i> , 2016, 34, 151-159.	1.7	107
20	Immunogenicity and Safety of a 9-Valent HPV Vaccine. <i>Pediatrics</i> , 2015, 136, e28-e39.	1.0	105
21	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. <i>Journal of Medical Virology</i> , 2001, 63, 1-7.	2.5	100
22	Distribution of Rotavirus Genotypes in Europe, 2004-2005: The REVEAL Study. <i>Journal of Infectious Diseases</i> , 2007, 195, S17-S25.	1.9	99
23	Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. <i>PLoS ONE</i> , 2013, 8, e66485.	1.1	97
24	Three decades of hepatitis B control with vaccination. <i>World Journal of Hepatology</i> , 2015, 7, 2127.	0.8	97
25	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	1.4	90
26	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 992-998.	1.1	89
27	Vaccination of healthcare personnel in Europe: Update to current policies. <i>Vaccine</i> , 2019, 37, 7576-7584.	1.7	86
28	Effect of a Prepregnancy Pertussis Booster Dose on Maternal Antibody Titers in Young Infants. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 608-610.	1.1	85
29	AS03 Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age. <i>Clinical Infectious Diseases</i> , 2010, 51, 668-677.	2.9	84
30	Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 2005-2014.	1.3	84
31	Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. <i>Pediatrics</i> , 2016, 138, .	1.0	84
32	Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. <i>Expert Review of Vaccines</i> , 2002, 1, 9-23.	2.0	80
33	Rotavirus Vaccines in Belgium. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, S21-S24.	1.1	79
34	Breastfeeding after maternal immunisation during pregnancy: Providing immunological protection to the newborn: A review. <i>Vaccine</i> , 2014, 32, 1786-1792.	1.7	78
35	The worldwide impact of vaccination on the control and protection of viral hepatitis B. <i>Digestive and Liver Disease</i> , 2011, 43, S2-S7.	0.4	76
36	Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. <i>BMC Infectious Diseases</i> , 2010, 10, 134.	1.3	75

#	ARTICLE	IF	CITATIONS
37	Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. <i>Vaccine</i> , 2016, 34, 3613-3619.	1.7	74
38	Hepatitis B Vaccines. <i>Journal of Infectious Diseases</i> , 2021, 224, S343-S351.	1.9	71
39	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. <i>Vaccine</i> , 2016, 34, 4205-4212.	1.7	68
40	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. <i>Frontiers in Immunology</i> , 2020, 11, 1282.	2.2	68
41	Long-term antibody persistence after vaccination with a 2-dose Havrix [®] (inactivated hepatitis A) Tj ETQq1 1 0.784314 rgBT /Overlook	1.7	65
42	A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review. <i>BMC Infectious Diseases</i> , 2015, 15, 425.	1.3	64
43	Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. <i>Vaccine</i> , 2007, 25, 4940-4948.	1.7	62
44	Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries. <i>Hum Vaccin</i> , 2011, 7, 734-748.	2.4	62
45	Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. <i>Vaccine</i> , 2014, 32, 1507-1513.	1.7	62
46	Timeliness of infant vaccination and factors related with delay in Flanders, Belgium. <i>Vaccine</i> , 2014, 32, 284-289.	1.7	62
47	Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults. <i>PLoS ONE</i> , 2011, 6, e25398.	1.1	62
48	Immunisation in the current management of cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2005, 4, 77-87.	0.3	61
49	The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. <i>Clinical Infectious Diseases</i> , 2016, 63, S197-S204.	2.9	60
50	Long-term Protection After Hepatitis B Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 214, 1-3.	1.9	60
51	Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 597-607.	1.9	59
52	Vaccination Coverage in 14-Year-Old Adolescents: Documentation, Timeliness, and Sociodemographic Determinants. <i>Pediatrics</i> , 2008, 121, e428-e434.	1.0	58
53	European Society for Paediatric Infectious Diseases Consensus Recommendations for Rotavirus Vaccination in Europe. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 635-643.	1.1	54
54	Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. <i>Vaccine</i> , 2015, 33, 4117-4123.	1.7	53

#	ARTICLE	IF	CITATIONS
55	Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. <i>Vaccine</i> , 2016, 34, 5785-5791.	1.7	53
56	Cost-effectiveness analysis of hepatitis A prevention in travellers. <i>Vaccine</i> , 1992, 10, S88-S92.	1.7	51
57	Epidemiology of <i>Trichomonas vaginalis</i> and Human Papillomavirus Infection Detected by Real-Time PCR in Flanders. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 273-280.	0.7	49
58	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	1.4	49
59	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet</i> , The, 2021, 397, 39-50.	6.3	49
60	Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. <i>Vaccine</i> , 2011, 29, 4698-4703.	1.7	47
61	Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders. <i>Vaccine</i> , 2018, 36, 6282-6289.	1.7	47
62	Hepatitis B control in Europe by universal vaccination programmes: The situation in 2001. <i>Journal of Medical Virology</i> , 2002, 67, 433-439.	2.5	46
63	12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	1.4	46
64	A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. <i>Expert Review of Vaccines</i> , 2004, 3, 249-267.	2.0	45
65	Vaccination during pregnancy: current and possible future recommendations. <i>European Journal of Pediatrics</i> , 2020, 179, 235-242.	1.3	44
66	Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. <i>Eurosurveillance</i> , 2016, 21, .	3.9	44
67	Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days. <i>Clinical Infectious Diseases</i> , 2019, 68, 607-614.	2.9	43
68	Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 72-80.	2.9	43
69	Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years. <i>Journal of Medical Virology</i> , 2011, 83, 1885-1891.	2.5	41
70	Overcoming barriers in HPV vaccination and screening programs. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 45-53.	4.5	41
71	Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2012, 30, F1-F11.	1.7	40
72	Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. <i>Vaccine</i> , 2004, 22, 305-308.	1.7	39

#	ARTICLE	IF	CITATIONS
73	Prevention of hepatitis A by Havrix®, a review. <i>Expert Review of Vaccines</i> , 2005, 4, 459-471.	2.0	39
74	Quantification of Vaccine-induced Antipertussis Toxin Secretory IgA Antibodies in Breast Milk. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e149-e152.	1.1	39
75	A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. <i>Vaccine</i> , 2016, 34, 5262-5272.	1.7	39
76	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. <i>International Journal of Cancer</i> , 2016, 139, 518-526.	2.3	38
77	Persistence of antibodies 20 years after vaccination with a combined hepatitis A and B vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 972-980.	1.4	38
78	Human papillomavirus detection in urine: Effect of a first-void urine collection device and timing of collection. <i>Journal of Virological Methods</i> , 2019, 264, 23-30.	1.0	38
79	Urine testing for HPV: rationale for using first void. <i>BMJ</i> , The, 2014, 349, g6252-g6252.	3.0	37
80	Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials. <i>Journal of Infectious Diseases</i> , 2018, 217, 1616-1625.	1.9	37
81	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA-Transfected Dendritic Cells. <i>Transplantation</i> , 2015, 99, 120-127.	0.5	36
82	Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. <i>Vaccine</i> , 2015, 33, 3976-3982.	1.7	36
83	GTLO01, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 3238-3248.	3.2	34
84	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100203.	4.5	34
85	Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 286-295.	4.6	34
86	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. <i>Npj Vaccines</i> , 2021, 6, 78.	2.9	34
87	Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 1186-1192.	1.1	33
88	Exploring the Impact of Exposure to Primary Varicella in Children on Varicella-Zoster Virus Immunity of Parents. <i>Viral Immunology</i> , 2011, 24, 151-157.	0.6	32
89	Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 859-869.	1.3	32
90	Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. <i>Bulletin of the World Health Organization</i> , 2018, 96, 484-497.	1.5	32

#	ARTICLE	IF	CITATIONS
91	A global prescription for adult immunization: Time is catching up with us. <i>Vaccine</i> , 2010, 28, 7137-7139.	1.7	31
92	Estimating the effective reproduction number for pandemic influenza from notification data made publicly available in real time: A multi-country analysis for influenza A/H1N1v 2009. <i>Vaccine</i> , 2011, 29, 896-904.	1.7	31
93	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11-15 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 627-634.	1.1	31
94	Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill & Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries. <i>Clinical Infectious Diseases</i> , 2016, 63, S123-S133.	2.9	31
95	Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. <i>Vaccine</i> , 2016, 34, 757-761.	1.7	31
96	Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to <i>Bordetella pertussis</i> antigens in maternal and cord sera of Thai women. <i>Vaccine</i> , 2018, 36, 1453-1459.	1.7	31
97	Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1066-1075.	1.0	31
98	Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium). <i>Vaccine</i> , 2011, 29, 8390-8396.	1.7	30
99	Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100185.	4.5	30
100	Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122.	1.7	30
101	Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020). <i>Vaccine</i> , 2022, 40, 151-161.	1.7	30
102	Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. <i>Vaccine</i> , 2002, 20, 2597-2602.	1.7	29
103	Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 1307-1312.	0.7	29
104	Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial. <i>Vaccine</i> , 2011, 29, 9376-9384.	1.7	29
105	Nasopharyngeal <i>s. pneumoniae</i> carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. <i>Vaccine</i> , 2018, 36, 15-22.	1.7	29
106	Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1496-1519.	1.4	29
107	Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. <i>Current Medical Research and Opinion</i> , 2007, 23, 2729-2739.	0.9	27
108	Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 323-327.	1.4	27

#	ARTICLE	IF	CITATIONS
109	Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. <i>Vaccine</i> , 2016, 34, 3156-3163.	1.7	27
110	First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 1-11.	0.5	27
111	The effect of maternal antibodies on the cellular immune response after infant vaccination: A review. <i>Vaccine</i> , 2020, 38, 20-28.	1.7	27
112	The health and economic burden of rotavirus disease in Belgium. <i>European Journal of Pediatrics</i> , 2008, 167, 1409-1419.	1.3	26
113	Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians. <i>Vaccine Journal</i> , 2014, 21, 417-426.	3.2	26
114	COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	26
115	Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. <i>Vaccine</i> , 2014, 32, 4849-4854.	1.7	25
116	Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. <i>Cancer Prevention Research</i> , 2016, 9, 766-771.	0.7	25
117	Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. <i>Journal of Infectious Diseases</i> , 2016, 214, 1498-1506.	1.9	25
118	Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination. <i>Clinical Infectious Diseases</i> , 2019, 69, 797-804.	2.9	24
119	Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. <i>Travel Medicine and Infectious Disease</i> , 2003, 1, 219-226.	1.5	23
120	Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model. <i>BMC Public Health</i> , 2011, 11, 470.	1.2	23
121	Environmental triggers of acute myocardial infarction: results of a nationwide multiple-factorial population study. <i>Acta Cardiologica</i> , 2015, 70, 693-701.	0.3	23
122	Follow-up of serotype distribution and antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. <i>Vaccine</i> , 2019, 37, 1080-1086.	1.7	23
123	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. <i>Vaccine</i> , 2021, 39, 2800-2809.	1.7	23
124	Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. <i>BMC Infectious Diseases</i> , 2010, 10, 357.	1.3	22
125	Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1109-1125.	2.4	22
126	Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials. <i>Vaccine</i> , 2011, 29, 5932-5939.	1.7	22

#	ARTICLE	IF	CITATIONS
127	Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?. <i>Vaccine</i> , 2012, 30, 2795-2800.	1.7	22
128	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 105-115.	4.5	22
129	Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. <i>Virulence</i> , 2017, 8, 1245-1254.	1.8	21
130	How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. <i>Eurosurveillance</i> , 2020, 25, .	3.9	21
131	Should Europe have a universal hepatitis B vaccination programme?. <i>BMJ, The</i> , 2013, 347, f4057-f4057.	3.0	20
132	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. <i>Vaccine</i> , 2014, 32, 3694-3705.	1.7	20
133	Surveillance of effects of HPV vaccination in Belgium. <i>Cancer Epidemiology</i> , 2016, 41, 152-158.	0.8	20
134	Effect of Prepregnancy Pertussis Vaccination in Young Infants. <i>Journal of Infectious Diseases</i> , 2017, 215, 1855-1861.	1.9	19
135	Memory CD4+ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus. <i>Genes and Immunity</i> , 2019, 20, 255-260.	2.2	19
136	Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	19
137	Coverage of the expanded program on immunization in Vietnam: Results from 2 cluster surveys and routine reports. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1526-1533.	1.4	18
138	Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better?. <i>Vaccine</i> , 2018, 36, 2687-2693.	1.7	18
139	From non school-based, co-payment to school-based, free Human Papillomavirus vaccination in Flanders (Belgium): A retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. <i>Vaccine</i> , 2015, 33, 5188-5195.	1.7	17
140	HPV DNA detection in urine samples of women: –an efficacious and accurate alternative to cervical samples?–™. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 755-757.	2.0	17
141	Case-Control Microbiome Study of Chronic Otitis Media with Effusion in Children Points at <i>Streptococcus salivarius</i> as a Pathobiont-Inhibiting Species. <i>MSystems</i> , 2021, 6, .	1.7	17
142	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV –positive tumour cells. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 1372-1380.	1.6	16
143	Is It Time for Vaccination to –Go Viral–?. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1343-1349.	1.1	16
144	Economic Evaluation of Vaccination. <i>Pharmacoeconomics</i> , 1996, 9, 8-15.	1.7	15

#	ARTICLE	IF	CITATIONS
145	Modelling forces of infection by using monotone local polynomials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2003, 52, 469-485.	0.5	15
146	Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing. <i>International Journal of Molecular Sciences</i> , 2016, 17, 750.	1.8	15
147	Triage of human papillomavirus infected women by methylation analysis in first-void urine. <i>Scientific Reports</i> , 2021, 11, 7862.	1.6	15
148	One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. <i>Vaccine</i> , 2022, 40, 196-205.	1.7	15
149	Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3746-3753.	1.4	14
150	Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria, 2010–2011. <i>Journal of Medical Virology</i> , 2015, 87, 401-406.	2.5	14
151	Prevalence of high-risk human papillomavirus and abnormal pap smears in female sex workers compared to the general population in Antwerp, Belgium. <i>BMC Public Health</i> , 2016, 16, 477.	1.2	14
152	First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. <i>Journal of Clinical Virology</i> , 2019, 117, 11-18.	1.6	14
153	Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country. <i>Contemporary Clinical Trials</i> , 2020, 99, 106189.	0.8	14
154	Can COVID-19 symptoms as reported in a large-scale online survey be used to optimise spatial predictions of COVID-19 incidence risk in Belgium?. <i>Spatial and Spatio-temporal Epidemiology</i> , 2020, 35, 100379.	0.9	14
155	In-depth analysis of pneumococcal serotypes in Belgian children (2015–2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. <i>Vaccine</i> , 2021, 39, 372-379.	1.7	14
156	Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. <i>Npj Vaccines</i> , 2021, 6, 94.	2.9	14
157	Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: Achieving the best of both worlds. <i>Vaccine</i> , 2014, 32, 345-349.	1.7	13
158	Long-term Antibody Persistence in Children After Vaccination With the Pediatric Formulation of an Aluminum-free Virosomal Hepatitis A Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e85-e91.	1.1	13
159	Herpes zoster is associated with herpes simplex and other infections in under 60 year-olds. <i>Journal of Infection</i> , 2015, 70, 171-177.	1.7	13
160	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
161	HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?. <i>International Journal of Infectious Diseases</i> , 2019, 88, 110-112.	1.5	13
162	mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 799-803.	0.4	13

#	ARTICLE	IF	CITATIONS
163	Response to diphtheria booster vaccination in healthy adults: vaccine trial. <i>BMJ: British Medical Journal</i> , 2000, 320, 217-217.	2.4	12
164	Immune Memory and Immune Response in Children From Bulgaria 5â€“15 Years After Primary Hepatitis B Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 51-53.	1.1	12
165	Should female sex workers be offered HPV vaccination?. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1544-1548.	1.4	12
166	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. <i>Annals of Global Health</i> , 2020, 86, 81.	0.8	12
167	Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results. <i>Journal of Infectious Diseases</i> , 2022, 226, 119-127.	1.9	12
168	Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1566-1575.	0.4	12
169	Safety and Immunogenicity of a Highâ€“Potency Inactivated Hepatitis A Vaccine. <i>Journal of Travel Medicine</i> , 1996, 3, 83-90.	1.4	11
170	Long-term persistence of humoral and cellular immune responses induced by an AS03_A-adjuvanted H1N1 2009 influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1512-1522.	1.4	11
171	The use of urine in the follow-up of HPV vaccine trials. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 350-352.	1.4	11
172	Assessment of the timely administration of the hepatitis B and BCG birth dose and the primary infant vaccination schedule in 2015â€“2016 in the Mekong Delta, Viet Nam. <i>Vaccine</i> , 2018, 36, 5760-5765.	1.7	11
173	Poliopolis: pushing boundaries of scientific innovations for disease eradication. <i>Future Microbiology</i> , 2019, 14, 1321-1330.	1.0	11
174	Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. <i>BMJ Open</i> , 2021, 11, e046835.	0.8	11
175	Preexisting memory CD4 T cells in naÃ“ve individuals confer robust immunity upon hepatitis B vaccination. <i>ELife</i> , 2022, 11, .	2.8	11
176	Repeated-measures models to evaluate a hepatitis B vaccination programme. <i>Statistics in Medicine</i> , 2001, 20, 951-963.	0.8	10
177	Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). <i>BMC Pediatrics</i> , 2010, 10, 42.	0.7	10
178	HPV immunization programs: Ensuring their sustainability and resilience. <i>Vaccine</i> , 2018, 36, 5219-5221.	1.7	10
179	Diagnosing enterovirus meningitis via blood transcriptomics: an alternative for lumbar puncture?. <i>Journal of Translational Medicine</i> , 2019, 17, 282.	1.8	10
180	Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine. <i>Molecules</i> , 2021, 26, 1989.	1.7	10

#	ARTICLE	IF	CITATIONS
181	Cost Effectiveness of Alternative Hepatitis A Immunisation Strategies. <i>Pharmacoeconomics</i> , 1995, 8, 5-8.	1.7	9
182	An Economic Evaluation of Hepatitis A Vaccination in Dutch Military Personnel. <i>Military Medicine</i> , 1998, 163, 564-567.	0.4	9
183	Strategies for Global Prevention of Hepatitis B Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2010, 659, 175-188.	0.8	9
184	Long-term Immunogenicity and Immune Memory After Two Doses of the Adult Formulation of a Combined Hepatitis A and B Vaccine in Children 1 to 11 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 703-705.	1.1	9
185	Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN- γ in patients with relapsing-remitting multiple sclerosis. <i>Innate Immunity</i> , 2016, 22, 266-273.	1.1	9
186	Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1800-1806.	1.4	9
187	An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix. <i>Vaccine</i> , 2019, 37, 2537-2553.	1.7	9
188	SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital. <i>Epidemiology and Infection</i> , 2021, 149, e172.	1.0	9
189	SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1755-1757.	1.0	9
190	Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report. <i>BMC Proceedings</i> , 2021, 15, 16.	1.8	9
191	Environmental triggers of acute myocardial infarction: results of a nationwide multiple-factorial population study. <i>Acta Cardiologica</i> , 2015, 70, 693-701.	0.3	9
192	CAREGIVERS' WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 61-63.	1.1	8
193	Reduced Prevalence of HBsAg Variants following a Successful Immunization Program in China. <i>Journal of Virology</i> , 2014, 88, 4605-4606.	1.5	8
194	Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	8
195	A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. <i>Vaccine</i> , 2017, 35, 6700-6706.	1.7	8
196	Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity. <i>Immunogenetics</i> , 2018, 70, 363-372.	1.2	8
197	Comparison of a VLP-based and GST μ -based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first void urine. <i>Journal of Medical Virology</i> , 2020, 92, 3774-3783.	2.5	8
198	Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium. <i>Family Practice</i> , 2022, 39, 92-98.	0.8	8

#	ARTICLE	IF	CITATIONS
199	Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e28573.	2.1	8
200	Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	3.9	8
201	Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol. <i>BMJ Open</i> , 2022, 12, e054688.	0.8	8
202	Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. <i>Vaccine</i> , 2015, 33, 3026-3034.	1.7	7
203	Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. <i>Viral Immunology</i> , 2016, 29, 169-175.	0.6	7
204	Recruitment barriers for prophylactic vaccine trials: A study in Belgium. <i>Vaccine</i> , 2017, 35, 6598-6603.	1.7	7
205	Poliopolis. <i>Lancet, The</i> , 2019, 394, 115.	6.3	7
206	Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework. <i>Vaccine</i> , 2019, 37, 6144-6153.	1.7	7
207	Low adherence with national travel medicine recommendations in Belgian expatriate children: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101424.	1.5	7
208	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234.	1.7	7
209	Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 445-446.	8.2	6
210	Hospital-wide SARS-CoV-2 antibody screening of staff in a university psychiatric centre in Belgium. <i>BJPsych Open</i> , 2021, 7, e40.	0.3	6
211	Efficacy of Influenza Immunisation Programmes Comparison of Two European Systems in One Practice. <i>European Journal of General Practice</i> , 2002, 8, 159-162.	0.9	5
212	Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. <i>Journal of Medical Virology</i> , 2009, 81, 1710-1715.	2.5	5
213	Estimating vaccination coverage for the trivalent measles-mumps-rubella vaccine from trivariate serological data. <i>Statistics in Medicine</i> , 2012, 31, 1432-1449.	0.8	5
214	Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: A Phase I dose escalating study in healthy volunteers. <i>Vaccine</i> , 2014, 32, 5118-5124.	1.7	5
215	Commentary to: Guide to tailoring immunization programmes in the WHO European Region. <i>Vaccine</i> , 2015, 33, 4385-4386.	1.7	5
216	Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. <i>Vaccine</i> , 2020, 38, 6914-6921.	1.7	5

#	ARTICLE	IF	CITATIONS
217	Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine. <i>Frontiers in Immunology</i> , 2020, 11, 1657.	2.2	5
218	A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3710-3728.	1.4	5
219	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. , 2001, 63, 1.		5
220	Evolving measles status and immunization policy development in six European countries. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-15.	1.4	5
221	Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned. <i>Vaccine</i> , 2022, 40, 3470-3480.	1.7	5
222	Estimation of the Force of Infection from Current Status Data Using Generalized Linear Mixed Models. <i>Journal of Applied Statistics</i> , 2007, 34, 923-939.	0.6	4
223	The introduction of policies for human papillomavirus vaccination in Europe. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 291-298.	0.8	4
224	LESSONS LEARNED FROM A MEASLES OUTBREAK IN ANTWERP, BELGIUM. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 343-345.	1.1	4
225	Zoster in Monasteries: Some Clarification Needed. <i>Clinical Infectious Diseases</i> , 2012, 54, 305-306.	2.9	4
226	Two decades of hepatitis B vaccination in mentally retarded patients: Effectiveness, antibody persistence and duration of immune memory. <i>Vaccine</i> , 2012, 30, 4757-4761.	1.7	4
227	Multi-disease analysis of maternal antibody decay using non-linear mixed models accounting for censoring. <i>Statistics in Medicine</i> , 2015, 34, 2858-2871.	0.8	4
228	Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium. <i>Medicine (United States)</i> , 2019, 98, e15412.	0.4	4
229	Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium. <i>PLoS ONE</i> , 2020, 15, e0234740.	1.1	4
230	Stable HEV IgG seroprevalence in Belgium between 2006 and 2014. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1253-1260.	1.0	4
231	Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. <i>Vaccine</i> , 2020, 38, 1643-1651.	1.7	4
232	The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next Generation. <i>MSphere</i> , 2021, 6, .	1.3	4
233	Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blind, randomised, controlled phase 2 trial. <i>Liver International</i> , 2021, 41, 2318-2327.	1.9	4
234	Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo. <i>BMJ Global Health</i> , 2021, 6, e005726.	2.0	4

#	ARTICLE	IF	CITATIONS
235	Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. , 2001, 63, 1.		4
236	Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium. Journal of Infectious Diseases, 2020, , .	1.9	4
237	Legal and illegal drug use among female sex workers in bar and club prostitution in Belgium: A quantitative and qualitative study. Drugs: Education, Prevention and Policy, 2014, 21, 56-64.	0.8	3
238	Hepatitis A Vaccines. , 2017, , 99-108.		3
239	Knowledge about HIV in People with Schizophrenia: A General Population Comparison. Clinical Schizophrenia and Related Psychoses, 2011, 5, 80-86.	1.4	3
240	Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors?? Reply. Pharmacoeconomics, 2004, 22, 136-138.	1.7	2
241	What counts in cytometric analysis to document vaccine immunogenicity?. Human Vaccines and Immunotherapeutics, 2012, 8, 499-500.	1.4	2
242	Elucidating the difference in the kinetics of antibody titres of infants in Belgium and Vietnam. Vaccine, 2020, 38, 7079-7086.	1.7	2
243	â€Alternative abridged preventive regimens against rabies for children in high endemic countriesâ€™. Vaccine, 2020, 38, 5578-5579.	1.7	2
244	Sampling Site Matters When Counting Lymphocyte Subpopulations. PLoS ONE, 2012, 7, e41405.	1.1	2
245	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 2016, 11, e0165384.	1.1	2
246	Replacing vaccine paper package inserts: a multi-country questionnaire study on the acceptability of an electronic replacement in different target groups. BMC Public Health, 2022, 22, 156.	1.2	2
247	Detection of SARS-CoV-2 in young children attending day-care centres in Belgium, May 2020 to February 2022. Eurosurveillance, 2022, 27, .	3.9	2
248	Combined Two-Dose Hepatitis A and B Vaccine (AmBrix????). Drugs, 2003, 63, 214-215.	4.9	1
249	Editorial on â€œWhat is a potentially damaging vaccination delay in children younger than 2 years?â€™. Human Vaccines and Immunotherapeutics, 2016, 12, 2053-2056.	1.4	1
250	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. Future Microbiology, 2019, 14, 369-372.	1.0	1
251	Letter to the editor: female sex workers and HPV vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 126-127.	1.4	1
252	Transcriptomic profiling of different responder types in adults after a PriorixÂ® vaccination. Vaccine, 2020, 38, 3218-3226.	1.7	1

#	ARTICLE	IF	CITATIONS
253	The influenza vaccine for nursing and care professionals at emergency services in Flanders. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2719-2722.	1.4	1
254	Hepatitis B vaccination among GPs in Flanders, Belgium in 1999. <i>European Journal of General Practice</i> , 2001, 7, 77-78.	0.9	0
255	Nieuwe vaccins. <i>Bijblijven</i> (Amsterdam, Netherlands), 2015, 31, 535-554.	0.0	0
256	Re: Letter to the Editor: P. van Damme et al., <i>Vaccine</i> 34 (2016) 757â€“761, as a reply to Ryser et alâ€™s letter in <i>Vaccine</i> . <i>Vaccine</i> , 2016, 34, 4272.	1.7	0
257	Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination. <i>Cancer Epidemiology</i> , 2016, 45, 178-179.	0.8	0
258	Hepatitis A Vaccines. , 2021, , 115-125.		0
259	Hepatitis B Vaccines. , 2017, , 109-116.		0
260	Long-term protection after hepatitis A and B vaccination: an update. <i>Acta Gastro-Enterologica Belgica</i> , 2003, 66, 247-9.	0.4	0
261	Title is missing!. , 2020, 15, e0234740.		0
262	Title is missing!. , 2020, 15, e0234740.		0
263	Title is missing!. , 2020, 15, e0234740.		0
264	Title is missing!. , 2020, 15, e0234740.		0